<DOC>
	<DOCNO>NCT01643447</DOCNO>
	<brief_summary>The purpose study confirm Ulinastatin safe effective drug reduce incidence postoperative hepatic failure HCC patient . To evaluate Ulinastatin improve survival HCC patient .</brief_summary>
	<brief_title>Ulinastatin Preventing Postoperative Hepatic Failure Hepatocellular Carcinoma ( HCC )</brief_title>
	<detailed_description>Hepatocellular carcinoma ( HCC ) , serious disease high incidence home abroad , still show rise trend . Postoperative hepatic failure remain major reason liver resection 's failure . • As broad spectrum enzyme inhibitor , Ulinastatin valid therapeutical effect hepatic failure hepatic ischemia-reperfusion injury animal experiment . And restrain inflammatory mediator release . But 's lack clinical evidence Ulinastatin reduce incidence postoperative hepatic failure HCC patient The purpose study assess effort compare Ulinastatin 's drug protection patient hepatocellular carcinoma ( HCC ) postoperative hepatic failure evaluate Ulinastatin improve survival HCC patient .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>Urinastatin</mesh_term>
	<mesh_term>Glycyrrhizic Acid</mesh_term>
	<criteria>1 . Male female patient &gt; 35 year &lt; =55 year age . 2. confirmed case ( patient HCC ) 3 . Tumors radical remove resection volume 50 % 70 % . 4 . Criteria liver function : Child A level , serum bilirubin ≤ 1.5 time upper limit normal value , alanine aminotransferase aspartate aminotransferase ≤ 2 time upper limit normal value . 5 . No dysfunction major organ ; Blood routine , kidney function , cardiac function lung function basically normal . Hbg ≥ 90g/L , WBC ≥ 3.000 cells/mm³ , platelet ≥ 80.000 cells/mm³ . 6 . Karnofsky Performance Score performance 60 . 7 . Patients understand trial sign information consent . 1 . Patients undergone previous treatment Ulinastatin . 2 . Patients apparent cardiac , pulmonary , cerebronic renal dysfunction , may affect treatment liver cancer . 3 . Patients disease may affect treatment mention . 4 . Patients medical history malignant tumor . 5 . Subjects participate clinical trial . 6 . Extrahepatic metastasis , portal vein major vascular involvement . liver function : Child B C. 7 . Patients would sign consent trial .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>Ulinastatin</keyword>
	<keyword>Hepatic Failure</keyword>
</DOC>